🇺🇸 FDA
Patent

US 6133276

Compounds and methods for increasing endogenous levels of corticotropin-releasing factor

expired A61PA61P43/00A61P5/00

Quick answer

US patent 6133276 (Compounds and methods for increasing endogenous levels of corticotropin-releasing factor) held by Neurocrine Biosciences, Inc. expires Mon Oct 12 2020 00:00:00 GMT+0000 (Coordinated Universal Time). Status: expired.

Key facts

Applicant
Neurocrine Biosciences, Inc.
Grant date
Tue Oct 17 2000 00:00:00 GMT+0000 (Coordinated Universal Time)
Expiration
Mon Oct 12 2020 00:00:00 GMT+0000 (Coordinated Universal Time)
Claims
65
CPC classes
A61P, A61P43/00, A61P5/00